Gadofosveset trisodium
- Generic Name
- Gadofosveset trisodium
- Brand Names
- Vasovist
- Drug Type
- Small Molecule
- Chemical Formula
- C33H38GdN3Na5O14P
- CAS Number
- 193901-90-5
- Unique Ingredient Identifier
- 9430ZR8ZAN
- Background
Gadofosveset trisodium is an intravenous contrast agent used with magnetic resonance angiography(MRA), which is a non-invasive way of imaging blood vessels. The agent allows for the vascular system to be imaged more clearly by the MRA. In this way, gadofosveset trisodium is used to help diagnose certain disorders of the heart and blood vessels.
- Indication
Gadofosveset trisodium is indicated for use as a contrast agent in magnetic resonance angiography (MRA) to evaluate aortoiliac occlusive disease (AIOD) in adults with known or suspected peripheral vascular disease.
- Associated Conditions
- Aortoiliac Occlusive Disease
- Associated Therapies
- -
Feraheme As An MRI Contrast Agent For Pediatric Congenital Heart Disease
- Conditions
- Interventions
- First Posted Date
- 2016-04-26
- Last Posted Date
- 2022-12-28
- Lead Sponsor
- Paul Finn
- Target Recruit Count
- 17
- Registration Number
- NCT02752191
- Locations
- 🇺🇸
UCLA Medical Center, Los Angeles, California, United States
Dose-varied Evaluation of Ablavar-enhanced MR Angiography of the Central Veins of the Chest in Healthy Participants
- First Posted Date
- 2011-09-09
- Last Posted Date
- 2013-12-10
- Lead Sponsor
- Duke University
- Target Recruit Count
- 30
- Registration Number
- NCT01431300
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
Improved Diagnosis of Congenital Heart Disease by Magnetic Resonance Imaging Using Vasovist
- Conditions
- First Posted Date
- 2008-04-29
- Last Posted Date
- 2009-08-03
- Lead Sponsor
- Guy's Hospital
- Registration Number
- NCT00668824
- Locations
- 🇬🇧
Division of Imaging Sciences, London, United Kingdom
Renal MRA Crossover Study Comparing Multihance to Another Contrast Agent
- First Posted Date
- 2006-12-25
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Bracco Diagnostics, Inc
- Target Recruit Count
- 39
- Registration Number
- NCT00415805
- Locations
- 🇮🇹
Bracco Imaging, S.p.A, Milan, Italy
Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases
- Conditions
- Interventions
- Procedure: Bone scanDrug: 99mTc-methyl diphosphonateProcedure: Positron Emission Tomography (PET) scanDrug: 18F-Fludeoxyglucose (18F-FDG)Procedure: Computed Tomography (CT) scanDrug: 18F-Sodium Fluoride (18F-NaF)Procedure: Whole Body Magnetic Resonance Imaging (WB-MRI) scanDrug: Gadopentetate dimeglumineDrug: GadofosvesetDrug: Gadobutrol
- First Posted Date
- 2006-09-13
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 114
- Registration Number
- NCT00375830
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.